Humedix Co., Ltd.

A200670

KR7200670008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
33,950 ^KRW	+2.72%		-4.10%	+0.59%

2023	Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on September 27, 2022.	CI
2023	Humedix Co., Ltd.'s Equity Buyback announced on September 27, 2022, has expired with 145,877 shares, representing 1.58% for KRW 2,992.33 million.	CI

Humedix Co., Ltd. authorizes a Buyback Plan.

August 13, 2020

The Board of Directors of Humedix Co., Ltd. has authorized a buyback plan on August 14, 2020.

Latest news about Humedix Co., Ltd.

Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on September 27, 2022.	23-03-27	CI
Humedix Co., Ltd.'s Equity Buyback announced on September 27, 2022, has expired with 145,877 shares, representing 1.58% for KRW 2,992.33 million.	23-03-26	CI
Ensol Biosciences Inc. announced that it has received KRW 4.99999995 billion in funding from Humedix Co., Ltd.	23-02-19	CI
Ensol Biosciences Inc. announced that it expects to receive KRW 4.99999995 billion in funding from Humedix Co., Ltd.	23-02-09	CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on September 27, 2022.	22-12-27	CI
Humedix Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.	22-09-27	CI
Humedix Co., Ltd. authorizes a Buyback Plan.	22-09-26	CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on March 16, 2022.	22-09-16	CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on March 16, 2022.	22-09-16	CI
Humedix Co., Ltd.'s Equity Buyback announced on March 16, 2022, has expired with 136,591 shares, representing 1.46% for KRW 2,982.87 million.	22-09-15	CI
An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. for KRW 21.5 billion.	22-06-21	CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on March 16, 2022.	22-06-17	CI
Humedix Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.	22-03-15	CI
Humedix Co., Ltd. authorizes a Buyback Plan.	22-03-15	CI
Kineta, Inc. announced that it has received funding from Humedix Co., Ltd.	21-10-03	CI
Kineta, Inc. announced that it expects to receive funding from Humedix Co., Ltd.	21-09-29	CI
Huons Global : S.Korean consortium to produce 100 mln doses a month of Russia's Sputnik V vaccine	21-04-15	RE
Humedix Co., Ltd. announced that it has received KRW 45 billion in funding from a group of investors	21-04-05	CI
Humedix Co., Ltd. announced that it expects to receive KRW 45 billion in funding from a group of investors	21-04-01	CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.	21-02-23	CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.	21-02-23	CI
Humedix Co., Ltd.'s Equity Buyback announced on August 14, 2020, has expired with 121,545 shares, representing 1.28% for KRW 2,994.19 million.	21-02-17	CI
Tranche Update on Humedix Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.	20-11-23	CI
Humedix Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.	20-08-14	CI
Humedix Co., Ltd. authorizes a Buyback Plan.	20-08-13	CI

Humedix Co., Ltd. is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals .The Companyâs main products consist of preparations for the treatment of arthritis, prescription drugs, medicament for the eyes, active pharmaceutical ingredients (APIs), as well as cosmetics and others. The Company distributes its products within domestic market and to overseas markets

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

33,950 KRW

Average target price

56,000 KRW

Spread / Average Target

+64.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUMEDIX CO., LTD.	+0.59%	255M
ELI LILLY AND COMPANY	+32.01%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.52%	371B
MERCK & CO., INC.	+20.01%	331B
ABBVIE INC.	+7.24%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.38%	169B

Other Pharmaceuticals

Humedix Co., Ltd.

Equities

A200670

KR7200670008

Pharmaceuticals

Humedix Co., Ltd. authorizes a Buyback Plan.

Latest news about Humedix Co., Ltd.

Chart Humedix Co., Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals